Two-week treatment with pravastatin improves ventriculo-vascular haemodynamic interactions in young men with type 1 diabetes

Abstract

Young patients with diabetes but without established vascular disease have altered conduit and resistance artery reactivity. Early endothelial dysfunction is an initial step in atherogenesis: reductions in nitric oxide (NO) production in these vascular beds are implicated.

The study aim was two-fold: first, to detect baseline abnormalities in cardiac function, conduit vessels and the microcirculation using applanation tonometry, brachial artery ultrasound and laser Doppler fluximetry, respectively; and second, to investigate any modification in these parameters with the use of pravastatin.

Nine young men with diabetes and normoalbuminuria were randomised in a double-blind cross-over fashion to placebo or pravastatin (40 mg) treatment for two weeks. They underwent scans on three separate occasions. Control patients (n=12) underwent a baseline scan but were not given any drug treatment.

It was found that patients with diabetes had significantly higher systolic and diastolic blood pressures, heart rate and Buckberg index (propensity to myocardial ischaemia). Brachial artery reactivity and microcirculatory dilation were both reduced. Levels of von Willebrand Factor, a marker of endothelial damage, were also elevated. Pravastatin treatment restored these sub-clinical abnormalities towards normal levels.

In conclusion, pravastatin improves vascular abnormalities in young male patients with diabetes through alterations in microcirculation and conduit vessel function, with secondary myocardial effects. This may be of benefit in preventing end-organ injury.

Keywords

applanation tonometry flow-mediated dilatation (FMD)laser Doppler fluximetry diabetes von Willebrand Factor pravastatin

References

1. Yamagishi S , Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Dis 2005;11:2279–99.

2. Atkinson MA , Eisenbarth GS. Type-1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221–9.

3. Clarkson P , Celermajer DS , Donald AE. et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low-density lipoprotein cholesterol levels. J Am Coll Cardiol 1996;28:573–9.

4. Meeking DR , Cummings MH , Thorne S. et al. Endothelial dysfunction in type 1 diabetic subjects with and without microalbuminuria. Diabet Med 1999;16:841–7.

5. Kilo S , Berghoff M , Hilz M , Freeman R. Neural and endothelial control of microcirculation in diabetic peripheral neuropathy. Neurology 2000;54:1246–52.

6. Ii M , Nichimura H , Kusano KF. et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation 2005;112:93–102.

7. Gooding KM , Hannemann MM , Tooke JE , Clough GF , Shore AC. Maximum skin hyperaemia induced by local heating: possible mechanisms. J Vasc Res 2006;43:270–7.

8. Goligorsky MS , Chen J , Brodsky S. Endothelial cell dysfunction leading to diabetic nephropathy. Hypertension 2001;37:744–8.

9. Carrier GO , White RE. Enhancement of alpha-1 and alpha-2 adrenergic agonist-induced vasoconstriction by removal of endothelium in rat aorta. J Pharmacol Exp Ther 1984;232:682–7.

10.

10. Lee BC , Stockman AJ , Shore AC , Tooke JE. Flow-related brachial artery dilation is impaired in subjects with fasting hyperglycaemia. Diabetic Med 1998;15:A33.

11.

11. Morris SJ , Jaap AJ , Shore AC , Tooke JE. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in subjects with fasting hyperglycaemia. J Physiol 1996;49:14P.

12.

12. Shivalkar B , Shondt D , Goovaerts I. et al. Flow mediated dilatation and cardiac function in type 1 diabetes mellitus. Am J Cardiol 2006;97:77–82.

13.

13. Donaghue KC , Robinson J , McCredie R , Fung A , Silink M , Celermajer DS. Large vessel dysfunction in diabetic adolescents and its relationship to small vessel complications. J Ped Endocrinol Metab 1997;10:593–8.

14.

14. Cersosimo E , DeFronzo RA. Insulin resistance and endothelial dysfunction: the roadmap to cardiovascular diseases. Diabetes Metab Res Rev 2006;22:423–36.

15.

15. Stehouwen CD , Stroes ES , Hackeng WH. et al. Von Willebrand factor and development of diabetic nephropathy in IDDM. Diabetes 1991;40:971–6.

16.

16. Jensen T , Bjerre Knudsen J , Feldt Rasmussen B , Deckert T. Features of endothelial dysfunction in early diabetic nephropathy. Lancet 1989;1:461–3.

17.

17. Jager A , Van Husbergh VW , Kostense PJ. et al. Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the HOORN study. Arterio Thromb Vasc Biol 1999;19:3071–8.

18.

18. Pyorala K , Pedersen TR , Kjekshus J , Faergeman O , Olsson AG , Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997;20:614–20.

19.

19. Sasaki J , Iwashita M , Kono S. Statins: beneficial or adverse for glucose metabolism. J Artheroscler Thromb 2006;13:123–9.

20.

20. Schoenhagen P , Tuzcu EM , Apperson-Hansen C et al. Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. Circulation 2006;113:2826–34.

21.

21. Goldberg RB , Mellies MJ , Sacks FM. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels subgroup analyses in the Cholesterol And Recurrent Events (CARE) trial. Circulation 1998;98:2513–19.

22.

22. Shepherd J , Cobbe SM , Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. (WOSCOPS study). New Engl J Med 1995;333:1301–07.

23.

23. Harris MB , Blackstone MA , Sood SG. et al. Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 2004;284:560–6.

24.

24. Joyce M , Moore K , Thompson C. et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition improves endothelial dysfunction in type-1 diabetes. Eur J Endovasc Surg 2004;27:432–7.

25.

25. Wagner AH , Kohler T , Ruckschloss U , Just I , Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000;20:61–9.

26.

26. John S , Schlaich M , Langenfeld M. et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. Circulation 1998;98:211–16.

27.

27. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol 2001;21:3–7.

28.

28. Fennessy F , Moneley DS , Wang JH , Kelly CJ , Bouchier-Hayes DJ. Taurine and vitamin C modify monocyte and endothelial dysfunction in young smokers. Circulation 2003;107:410–15.

29.

29. O'Grady HL , Leahy A , McCormick PH , Fitzgerald P , Kelly CK , Bouchier-Hayes DJ. Oral folic acid improves endothelial dysfunction in cigarette smokers. J Surg Res 2002;106:342–5.

30.

30. Anderson TJ , Uehata A , Gerhard MD. et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235–41.

31.

31. Kelly R , Hayward C , Ganis J , Daley J , Avolio A , O'Rourke M. Noninvasive registration of the arterial pressure pulse waveform using high fidelity applanation tonometry. J Vasc Med Biol 1989;1:142–9.

32.

32. O'Rourke MF , Avolio AP , Karamanoglu M. Use of transfer functions to determine central from peripheral pressure pulse. J Am Coll Cardiol 1992;19:1652–9.

33.

33. Chen CH , Nevo E , Fetics B. et al. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Circulation 1987;7:1827–36.

34.

34. Kelly RP , Gibbs HH , O'Rourke MF et al. Nitroglycerin has more favourable effects on left ventricular afterload than apparent from measurements of pressure in a peripheral artery. Eur Heart J 1990;11:138–44.

35.

35. Brooks B , Molyneaux L , Yue DK. Augmentation of central arterial pressure in type-1 diabetes. Diabetes Care 1999;22:1722–7.

36.

36. Wilkinson IB , MacCallum H , Rooijmans DF. et al. Increased augmentation index and systolic stress in type 1 diabetes mellitus. QJM 2000;93: 441–8.

37.

37. Wilson SB , Jennings PE , Belch JJ. Detection of microvascular impairment in type 1 diabetics by laser Dopplerflowmetry. Clin Physiol 1992;12:195–208.

38.

38. Cochrane T , Sheriff SB , Boulton AJ , Ward JD , Atkins RM. Laser Doppler flowmetry in the assessment of peripheral vascular disorders. A preliminary evaluation. Clin Phys Physiol Meas 1986;7:31–42.

39.

39. Bornmyr S , Svensson H , Lilja B , Sundkvist G. Cutaneous vasomotor responses in young type 1 diabetic patients. J Diabetic Complications 1997;11:21–6.

40.

40. Cotter MA , Cameron NE. Correction of neurovascular deficits in diabetic rats by beta2-adrenoceptor agonist and alpha1-antagonist treatment: interactions with the nitric oxide system. Eur J Pharmacol 1998;343:217–23.

41.

41. Zatz R , Brenner BM. Pathogenesis of diabetic microangiopathy. Am J Med 1986;80:443–53.

42.

42. Belcaro G , Vasdekis S , Rulo A , Nicolaides AN. Evaluation of skin blood flow and venoarteriolar response in patients with diabetes and peripheral vascular disease by laser Doppler flowmetry. Angiology 1989;40:953–7.

43.

43. Sandeman DD , Dhore AC , Tooke JE. Relation of skin capillary pressure in patients with insulin-dependent diabetes to complications and metabolic control. N Engl J Med 1992;327:760–4.

44.

44. Belcaro G , Grigg M , Rulo A , Nicolaides A. Blood flow in the perimalleolar skin in relation to posture in patients with venous hypertension. Ann Vasc Surg 1989;3:5–7.

45.

45. Corsi M , Lacerna F , Borzone A , Belcaro G. Macro- and microcirculation study in diabetic patients. Minerva Cardioangiol 1996;44:535–7.

46.

46. Buckberg GD , Fixler DE , Archie JP , Hoffman JIE. Experimental subendocardial ischaemia in dogs with normal coronary arteries. Circ Res 1972;30:37–81.

47.

47. Buckberg GD , Towers B , Paglia DE , Mulder DG , Maloney JV. Subendocardial ischemia after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1972;64:669–85.

48.

48. Agewall S , Wright S , Doughty RN , Whalley GA , Duxbury M , Sharpe N.

Does a glass of red wine improve endothelial function?

Eur Heart J 2000;21:74–8.

49.

49. Bots ML , Westerlink J , Rabelink TJ , de Koning EJ. Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: effects of technical aspects of the FMD measurement on the FMD response. Eur Heart J 2005;26:363–8.

50.

50. Nabel EG , Selwyn AP , Ganz P. Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol 1990;16:349–56.

51.

51. Zenere BM , Arcaro F , Saggiani F , Rossi L , Muggeo M , Lechi A. Noninvasive detection of functional alterations of the arterial wall in IDDM patients with and without microalbuminuria. Diabetes Care 1995;18:975–82.

52.

52. McFarlane R , McCredie RJ , Bonney MA. et al. Angiotensin converting enzyme inhibition and arterial endothelial function in adults with type 1 diabetes mellitus. Diabet Med 1999;16:62–6.

53.

53. Lambert J , Aarsen M , Donker AJM , Stehouwer CDA. Endothelium-dependent and -independent vasodilatation of large arteries in nor-moalbuminuric insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996;16:705–11.

54.

54. Smits P , Kapma J , Jacobs M , Lutterman J , Thien T. Endothelium-dependent vascular relaxation in patients with type-1 diabetes. Diabetes 1993;42:148–53.

55.

55. Williamson JR , Chang K , Frangos M. et al. Hyperglycaemic pseudohypoxia and diabetic complications. Diabetes 1993;42:801–13.

56.

56. Scherrer U , Randin D , Vollenweider P , Vollenweider L , Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994;94:2511–15.

57.

57. Cotter MA , Love A , Watt MJ , Cameron NE , Dines KC. Effect of natural free radical scavengers on peripheral nerve and neurovascular function in diabetic rats. Diabetologia 1995;38:1285–94.

58.

58. Cameron NE , Cotter MA , Robertson S. Angiotensin converting enzyme inhibition prevents the development of muscle and nerve dysfunction and stimulates angiogenesis in streptozotocin-diabetic rats. Diabetologia 1992;35:12–18.

59.

59. Kador PF. The role of aldose reductase in the development of diabetic complications. Med Res Rev 1998;8:325–52.

60.

60. Stevens MJ , Lattimer SA , Kamijo M , Van Huysen C , Sima AA , Greene DA. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia 1993;36:608–14.

61.

61. Greene DA , Lewis RA , Lattimer SA , Brown MJ. Selective effects of myoinositol administration on sciatic and tibial motor nerve conduction parameters in streptozotocin-diabetic rats. Diabetes 1995;44:234–42.

62.

62. Hong HJ , Loh SH , Yen MH. Suppression of the development of hypertension by the inhibitor of inducible nitric oxide synthase. Br J Pharmacol 2000;131:631–7.

63.

63. Peng HB , Spieker M , Liao JK. Inducible nitric oxide: an autoregulatory feedback inhibitor of vascular inflammation. J Immunol 1998;161:1970–6.

64.

64. Guzik TJ , Korbut R , Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 2003;54:469–87.

65.

65. Wagner AH , Schwabe O , Hecker M. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 2002;136:143–9.